Addex Therapeutics Statistics
Total Valuation
ADXN has a market cap or net worth of $6.47 million. The enterprise value is $5.44 million.
Important Dates
The last earnings date was Thursday, June 25, 2026, before market open.
| Earnings Date | Jun 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADXN has 119.32 million shares outstanding. The number of shares has increased by 14.34% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 119.32M |
| Shares Change (YoY) | +14.34% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 18.65% |
| Owned by Institutions (%) | 1.81% |
| Float | 97.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.37 |
| Forward PS | n/a |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 39.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.97 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -950.19 |
Financial Efficiency
Return on equity (ROE) is -122.28% and return on invested capital (ROIC) is -28.66%.
| Return on Equity (ROE) | -122.28% |
| Return on Assets (ROA) | -23.59% |
| Return on Invested Capital (ROIC) | -28.66% |
| Return on Capital Employed (ROCE) | -76.00% |
| Weighted Average Cost of Capital (WACC) | 14.86% |
| Revenue Per Employee | $45,503 |
| Profits Per Employee | -$2.90M |
| Employee Count | 3 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.73% in the last 52 weeks. The beta is 1.97, so ADXN's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | -33.73% |
| 50-Day Moving Average | 6.64 |
| 200-Day Moving Average | 7.73 |
| Relative Strength Index (RSI) | 44.06 |
| Average Volume (20 Days) | 5,379 |
Short Selling Information
The latest short interest is 1,344, so 0.12% of the outstanding shares have been sold short.
| Short Interest | 1,344 |
| Short Previous Month | 4,982 |
| Short % of Shares Out | 0.12% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.45 |
Income Statement
In the last 12 months, ADXN had revenue of $136,508 and -$8.69 million in losses. Loss per share was -$0.08.
| Revenue | 136,508 |
| Gross Profit | -551,312 |
| Operating Income | -3.35M |
| Pretax Income | -8.83M |
| Net Income | -8.69M |
| EBITDA | -3.35M |
| EBIT | -3.35M |
| Loss Per Share | -$0.08 |
Full Income StatementBalance Sheet
The company has $1.17 million in cash and $127,498 in debt, giving a net cash position of $1.04 million or $0.01 per share.
| Cash & Cash Equivalents | 1.17M |
| Total Debt | 127,498 |
| Net Cash | 1.04M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 4.10M |
| Book Value Per Share | 0.03 |
| Working Capital | -40,592 |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.92M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -1,961 |
| Net Borrowing | -8,729 |
| Free Cash Flow | -2.89M |
| FCF Per Share | -$0.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -2,455.04% |
| Pretax Margin | -6,467.34% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |